

## Organisation

<b>Unit Head and Principal Investigator</b>	Dr. P.D. Aude Ambresin
<b>Clinical Research Coordinators</b>	Daniela Gallo Castro, PhD Yannic Pannatier-Schuetz, PhD Anna Chiara Nascimbeni
<b>Optometrist Referent</b>	Lucie Faillot
<b>Nurse Referent</b>	Alexandrina Oliveira Fernandes
<b>Data Manager</b>	Baptiste Crozat
<b>Biostatisticien</b>	Pathé Barry
<b>Medical Fellows</b>	Dr. Yoan Perez - 2023 Dr. Mihaela Chitoroaga - 2023 Dr. Nicolas Owlya - 2022 Dr. Mickael Barbosa - 2022 Dr. Coraline Calci - 2021 Dr. Georgios N. Tsiropoulos - 2020 Dr. Vasilea Chatzistergiou - 2019 Dr. Giorgio E. Bravetti - 2018 Dr. Ioannis Papasavvas - 2017

## MULTICENTRIC studies

### Ongoing

- PULSAR (Bayer) - Randomized, Double-Masked, Active-Controlled, Multi-Center Study Of Efficacy And Safety Of Intravitreal High Dose Aflibercept (8 mg) In Patients With Neovascular Age-Related Macular, PI 2021-2024.
- QUASAR (Bayer) - Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion, Bayer, PI 2023-2025.
- SANDCAT (Roche) - A phase III, multicenter, randomized, double masked, sham-controlled study to investigate the efficacy, safety, pharmacokinetics, and pharmacodynamics of anti-IL6 in adult patients with uveitic macular edema.
- VOYAGER (Roche) - Real-world, long-term data collection to gain clinical insights into Roche ophthalmology products.
- INTERCEPT-AMD – A collaborative resource of Heidelberg multimodal imaging of Intermediate AMD with and without early atrophy to study prediction of disease progression, in collaboration with the EVICR.net, 2023-2024.
- SPECTRUM (Bayer) – An observational study program to investigate the effectiveness of aflibercept 8mg used in nDME and nAMD in a real-world setting.

### Completed

- Real-Life Outcomes of adjunct intravitreal Dexamethasone Implant (Ozurdex) in Patients treated with anti-VEGF drugs for Diabetic Macular Edema and Exudative Age-Related Macular Degeneration, in collaboration with Berner Augenklinik am Lindenhofspital, 2022.
- FALCON (Novartis) - A 52-week, two arm, randomized, open-label, multicenter study assessing the efficacy and safety of two different brolucizumab 6 mg dosing regimens for patients with suboptimal anatomically controlled neovascular age-related macular degeneration. PI 2021-2022.
- Consensus visual OCT priming study wetAMD, in collaboration with the Institute of Molecular and Clinical Ophthalmology Basel, the University Hospital Basel and the University of Applied Sciences Northwestern Switzerland, 2022.
- Global nAMD & DR Barometer Survey. A multi-country patient and clinician survey to investigate patients' and clinical peers' perspectives, trends and practice patterns, relevant to the delivery of care for nAMD and DR, 2022.
- The brolucizumab RAPTOR BRVO study RTH258C2301 (Novartis) - An Eighteen-Month, Two-Arm, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Macular Edema secondary to Branch Retinal Vein Occlusion, PI 2019-2021.
- XTEND (Bayer) – Evaluation of an eXtended and proacTive dosing regimEn in treatment-Naïve patients with wet age-related macular Degeneration (wAMD), PI , 2019.

- A Phase 2, randomised, single-masked, active-controlled, multicentre study to evaluate the efficacy and safety of intravitreal THR-317 administered in combination with ranibizumab, for the treatment of diabetic macular oedema (DME), PI, 2018-2019.
- Efficacy and Safety of RTH258 versus Aflibercept Long Title A Two-Year, Randomized, Double-Masked, Multicenter, Two-Arm Study Comparing the Efficacy and Safety of RTH258 6 mg Versus Aflibercept in Subjects with Neovascular Age-Related Macular Degeneration, sub PI, 2015-2017.
- Allergan Abicipar Pegol 150998-005 (CEDAR) Study: The Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients with Neovascular Age related Macular Degeneration, PI, 2016-2017.
- A 24-month, phase IIIb, open-label, randomized, active controlled, 3-arm, multicenter study assessing the efficacy and safety of an individualized, stabilization-criteria-driven PRN dosing regimen with 0.5-mg ranibizumab intravitreal injections applied as monotherapy or with adjunctive laser photocoagulation in comparison to laser photocoagulation in patients with visual impairment due to macular edema secondary to branch retinal vein occlusion (BRVO) Brighter Study Principal Investigator.
- A 24-month, phase IIIb, open-label, single arm, multicenter study assessing the efficacy and safety of an individualized, stabilization criteria-driven PRN dosing regimen with 0.5-mg ranibizumab intravitreal injections applied as monotherapy in patients with visual impairment due to macular edema secondary to central retinal vein occlusion (CRVO) Crystal Study Principal Investigator.
- A 12-month, randomized, double-masked, sham-controlled, multicenter study to evaluate the efficacy and safety of 0.5mg ranibizumab intravitreal injections in patients with visual impairment due to vascular endothelial growth factor (VEGF) driven choroidal neovascularization (CNV), closed sub PI Minerva Study.
- A 12-month, randomized, double-masked, sham-controlled, multicenter study to evaluate the efficacy and safety of 0.5mg ranibizumab intravitreal injections in patients with visual impairment due to vascular endothelial growth factor (VEGF) driven macular edema (ME), Prometheus study, Sub PI.
- A 12-month, phase IIIb, randomized, visual acuity assessor-masked, multicenter study assessing the efficacy and safety of ranibizumab 0.5mg in TReat and extEND regimen compared to monthly regimen, in patients with neovascular age-related macular degeneration, Sub PI.
- A 24 month phase IIIb randomized multicenter study assessing safety and efficacy of two treatment regimens of 0.5mg ranibizumab intravitreal guided by functional and /or anatomical criteria in patients with neovascular AMD (OCTAVE), Sub PI.
- A Phase 3, randomized, Double-Masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreal Administration of Fovista™ (anti PDGF-B Pegylated Aptamer) Administered in Combination with Lucentis® Compared to Lucentis® Monotherapy in Subjects with Subfoveal Neovascular Age-Related Macular Degeneration Fovista™, Sub PI.
- A 12 month phase III study to evaluate efficacy and safety of two different dosing regimen of 0.5mg ranibizumab vs verteporfin PDT in patients with visual impairment due to choroidal CNV secondary to pathologic myopia, Radiance Study, Principal investigator.
- A 12 month, phase III, randomized, double-masked, multi-center, active-controlled study to evaluate the efficacy and safety of two different dosing regimens of 0.5 mg ranibizumab vs. verteporfin PDT in patients with visual impairment due to choroidal neovascularization secondary to pathologic myopia, Mont Blanc Study, Principal Investigator.

## MONOCENTRIC STUDIES

### Ongoing

- Barbosa M, Ambresin A, Switch from Aflibercept to Faricimab in patients with neovascular age-related macular degeneration.
- Barbosa M, Ambresin A, Efficacy and durability of faricimab intravitreal injections in naïve patients with wet age-related macular degeneration.
- Owlya N, Ambresin A, Intravitreal Faricimab in patients treated for refractory diabetic macular edema.
- Calci C, Barbosa M, Owlya N, Ambresin A, Evolution of acute intraocular pressure elevations following intravitreal anti-VEGF injections over one year of treatment.

### Future

- Owlya N, Ambresin A, Photobiomodulation therapy in patients with early to intermediate dry age-related macular degeneration.

### Completed

- Chatzistergiou V, Ambresin A, Influence of structural spectral-domain optical coherence tomography characteristics in the detection of choroidal neovascularization due to age-related macular degeneration using optical coherence tomography angiography.
- Vitamin A deficiency - Chatzistergiou V, Ambresin A, Markedly Delayed Night Blindness Due to Vitamin A Insufficiency Secondary to Bowel Resection, Published study.
- AZM RD - Chatzistergiou V, Ambresin A., Optical Coherence Tomography Analysis of Cystoid Macular Edema in Retinal Dystrophy Treated with Oral Acetazolamide: Two Cases, Published study.
- Fovea plana/hypoplasia - Chatzistergiou V, Ambresin A, Foveal Hypoplasia on Optical Coherence Tomography Angiography: New perspectives, Published study.
- COVID-RV – Tsiropoulos G N, Ambresin A, Five cases of retinal vascular anomalies after COVID-19: A case series, 1 Free paper.
- COVID\_AMD – Tsiropoulos G N, Ambresin A, The importance of monitoring wet AMD patients during COVID-19 pandemic: A retrospective study of assessment of functional and structural outcomes, Published study.
- COVID\_AMD – Tsiropoulos G N, Ambresin A, Patient opinion on the monitoring of their wet age related macular degeneration during coronavirus disease 2019 pandemic and on the importance of telemedicine, 1 Free paper.
- Temps circ - OCTA vs Fluo – Körpe D, Ambresin A, Influence des variations des temps circulatoires rétiniens et choroïdiens mesurés en angiographie avec produit de contraste sur l'analyse quantitative obtenue en OCT-angiographie, 2 posters, Manuscript under redaction.

## PUBLICATIONS (SINCE 2015)

### Peer-reviewed

- Meier PG, Ambresin A, Thirkill CE, Borruat FX, Schalenbourg A. Paraneoplastic vitelliform retinopathy secondary to metastatic melanoma. *Klin Monbl Augenheilkd.* 2015 Apr;232(4):587-9.
- Lehmann-Clarke L, Dirani A, Mantel I, Ambresin A, The effect of switching ranibizumab to aflibercept in refractory cases of macular edema secondary to ischemic central vein occlusion, *Klin Monbl Augenheilkd.* 2015 Apr;232(4):552-5.
- Ladaïque M, Dirani A, Ambresin A, Long-term follow-up of choroidal neovascularization in pathological myopia treated with intravitreal ranibizumab, *Klin Monbl Augenheilkd.* 2015 Apr;232(4):542-7.
- Dirani A, Mantel I, Ambresin A, Recurrent Macular Edema in Central Retinal Vein Occlusion Treated with Intravitreal Ranibizumab using a Modified Treat and Extend Regimen, *Klin Monbl Augenheilkd.* 2015 Apr;232(4):538-41.
- Ambresin A, Strueven V, Pournaras JA, Painless indirect argon laser in high risk proliferative diabetic retinopathy, *Klin Monbl Augenheilkd.* 2015 Apr;232(4):509-13.
- Gianniou C, Dirani A, Ferrini W, Marchionno L, Decugis D, Deli A, Ambresin A, Mantel I, Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration: how to alleviate the clinical burden with maintained functional results, *Eye (Lond).* 2015 Mar;29(3):450-1.
- Jang L, Gianniou C, Ambresin A, Mantel I, Refractory subretinal fluid in patients with neovascular age-related macular degeneration treated with intravitreal ranibizumab: visual acuity outcome, *Graefes Arch Clin Exp Ophthalmol.* 2015 Aug;253(8):1211-6.
- Massougnes S, Borruat FX, Ambresin A, Peripheral Bilateral Telangiectasiae in Multiple Sclerosis Patients Treated with Interferon B1a, *Klin Monbl Augenheilkd.* 2016 Apr;233(4):438-40.
- Massougnes S, Dirani A, Ambresin A, Decugis D, Marchionno L, Mantel I., Pigment epithelial detachment response to aflibercept in neovascular age-related macular degeneration refractory to ranibizumab: Time Course and Drug Effects, *Retina.* 2016 May;36(5):881-8.
- Matet A, Daruich A, Dirani A, Ambresin A, Behar-Cohen F, Macular Telangiectasia Type 1: Capillary Density and Microvascular Abnormalities Assessed by Optical Coherence Tomography Angiography, *Am J Ophthalmol.* 2016 Jul;167:18-30.
- Ambresin A, Borruat FX, [Hypertension and the eye]. *Rev Med Suisse.* 2015 Dec 16;11(499):2366, 2368-72. French.
- Dirani A, Ambresin A, Marchionno L, Decugis D, Mantel I, Factors Influencing the Treatment Response of Pigment Epithelium Detachment in Age-Related Macular Degeneration, *Am J Ophthalmol.* 2015 Oct;160(4):732-8.
- Kowalczyk L, Matet A, Dirani A, Daruich A, Ambresin A, Mantel I, Spaide RF, Turck N, Behar-Cohen F, Efficacy of intravitreal aflibercept in macular telangiectasia type 1 is linked to the ocular angiogenic profile, *Retina* 2017 Dec;37(12):2226-2237.
- Parvin P, Zola M, Dirani A, Ambresin A, Mantel I., Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration treated with Aflibercept, *Graefes Arch Clin Exp Ophthalmol* 2017 Nov;255(11):2127-2134.

- Daruich A, Matet A, Marchionno L, De Azevedo JD, Ambresin A, Mantel I, Behar-Cohen F., Acute central serous chorioretinopathy, Factors Influencing Episode Duration, *Retina*. 2017 Oct;37(10):1905-1915.
- Tam EK, Golchet P, Yung M, De Croos FC, Spirn M, Lehmann-Clarke L, Ambresin A, Tsui I., Ischemic central retinal vein occlusion in the anti-vascular endothelial growth factor era., *Retina* 2018 Feb;38(2):292-298.
- Nguyen NCI, Fabro F, Ambresin A, Ezziat S, Bergin C, Mazzocato C, Mantel I., Factors associated with pain during intravitreal injection of anti-vascular endothelial growth factor. *Eye (Lond)*. 2018 Sep;32(9):1544-1546.
- Roemer S, Bergin C, Kaeser PF, Ambresin A. Macular vasculature of children with sickle cell disease compared to healthy eyes using optical coherence tomography angiography. *Retina* 2019 Dec;39(12):2384-2391.
- Papasavvas I, Ambresin A, Pournaras JA, Henchoz L, Vaudaux J. Regression of Optic Disc Neovascularization (NVD) in a Patient with Behçet's Disease Treated with Oral Corticosteroids and Adalimumab (ADA). *Klin Monbl Augenheilkd*. 2019 Apr;236(4):578-580.
- Sherif M, Berthoud J, Pournaras JA, Ambresin A, OCT-Angiography as a Help in the Diagnosis of a Laser Pointer Retinal Injury: A Case Report, *Klin Monbl Augenheilkd*. 2019 Apr;236(4):594-597.
- Roquelaure D, Rossi DC, Ambresin A, Guex-Crosier Y. Vasculitis and Retrofoveal Choroidal Neovessels in a Case of Multifocal Pattern Dystrophy. *Klin Monbl Augenheilkd*. 2019 Apr;236(4):523-525.
- Kheir V, Ambresin A, Mantel I., Multiple serous pigment epithelial detachments in association with major weight loss: case report and review of the literature. *Retin Cases Brief Rep* 2020 Winter;14(1):72-76.
- Chatzistergiou V, Papasavvas I, Escher P, Durig J, Vaudaux J, Pournaras JA, Ambresin A. Optical coherence tomography analysis of cystoid macular edema in retinal dystrophy treated with oral acetazolamide: two cases, *Klin Monbl Augenheilkd*. 2020 Apr;237(4):484-486.
- Voide N, Mantel I, Ambresin A. Atypical Retro Internal Limiting Membrane Haemorrhage in Homozygous Sickle Cell Disease. *Klin Monbl Augenheilkd*. 2020 Apr;237(4):477-479.
- Gillmann K, Mansouri K, Ambresin A, Bravetti GE, Mermoud A. A Prospective Analysis of iStent Inject Microstent Implantation: Surgical Outcomes, Endothelial Cell Density, and Device Position at 12 Months. *J Glaucoma* 2020 Aug;29(8):639-647.
- Chatzistergiou V, Cilliers H, Pournaras JA, Ambresin A. Fovea Plana on Optical Coherence Tomography Angiography: New perspectives. *Retina* 2021 Jul 1;41(7):1541-1546.
- Chatzistergiou V, Ambresin A, Borruat FX. Markedly Delayed Night Blindness Due to Vitamin A Insufficiency Secondary to Bowel Resection. *Klin Monbl Augenheilkd*. 2021 Apr;238(4):428-430.
- Zola M, Ambresin A, Zografos L, Optical coherence tomography angiography imaging of a congenital simple hamartoma of the retinal pigment epithelium. *Retin Cases Brief Rep*. 2021 May 1;15(3):289-293.
- Chatzistergiou V, Papasavvas I, Ambresin A, Pournaras JC, Prediction of Postoperative Visual Outcome in Patients with Idiopathic Epiretinal Membrane. *Ophthalmologica*. 2021;244(6):535-542.

- Bravetti GE, Vaudaux J, Pournaras JA, Ambresin A. Persistent Remnants of Dexamethasone Intravitreal Implant Over 24 Months in a Patient Suffering from Anterior and Intermediate Uveitis Associated with Macular Edema. *Klin Monbl Augenheilkd*. 2021 Apr;238(4):454-457.
- Moret E, Ambresin A, Gianniou C, Bijon J, Besse-Hayat C, Bogiatzi S, Hohl D, Spertini F, Mantel I. Non-immediate drug hypersensitivity reactions secondary to intravitreal anti-vascular endothelial growth factors. *Graefes Arch Clin Exp Ophthalmol*. 2022 Mar;260(3):1005-1014.
- Tsiropoulos GN, Castro DG, Ambresin A, Six Cases of Retinal Vascular Anomalies after Coronavirus Disease 2019: A case Series, *Klin Monbl Augenheilkd*. 2022 Apr;239(4):537-544.
- Tsiropoulos GN, Vallee R, Gallo Castro D, Ambresin A. The importance of monitoring wet age-related macular degeneration patients during Coronavirus disease 19 pandemic: A retrospective study of assessment of functional and structural outcomes. *J Fr Ophtalmol*. 2022 Jul 6;45(8):852–9.
- Georgios N. Tsiropoulos, Rodolphe Vallée, Coraline Calci, Daniela Gallo Castro, Aude Ambresin. Patient perspective on the monitoring of their wet age-related macular degeneration during coronavirus disease 2019: a retrospective study. *Medicina (Kaunas)*. 2023 Mar 2;59(3):490.
- Calci C, Gallo Castro D, Daniela Gallo; Pannatier Schuetz YB, Mermoud A, Ambresin A, Rapidly Progressive Visual Field Deterioration in a Glaucomatous Patient Treated with Several Anti-VEGF Injections for Neovascular AMD, A Case Report, *Klin Monatsbl Augenheilkd* 2023; 240(04): 478-480.
- El Karmy B, Gallo Castro D, Ambresin A, Preventive inflammation management with steroids before retreatment with anti-VEGF after severe inflammation due to brolicizumab, *Klin Monatsbl Augenheilkd* 2023; 240(4): 556-562.

#### Submitted

- Dilsah Körpe, Georgios N. Tsiropoulos, Rodolphe Vallée, Daniela Gallo Castro, Irmela Mantel, Constantin J Pournaras, Aude Ambresin. Influence of retinal perfusion times measured using dye angiography on the quantitative analysis of OCT-angiography.
- Ioannis Papisavvas, Vasileia Chatzistergiou, Rodolphe Vallée, Ali Dirani, Jean-Antoine Pournaras, Aude Ambresin. Influence of structural spectral-domain optical coherence tomography characteristics in the detection of neovascularization due to age-related macular degeneration using optical coherence tomography angiography.
- Chaudhary V, Ambresin A, Kotecha A, Willis JR, Souverain A, Shildkrot YE, Swaminathan B, Margaron P. Personalised faricimab dosing increased the proportion of patients with nAMD achieving Q16W dosing in year 2 of TENAYA/LUCERNE, while maintaining functional and anatomical outcomes.



## CONFERENCES (SINCE 2018)

### Invited Speaker

- Biomarkers in clinical diagnosis of wet AMD; Retina French Society, Prof Coscas, Paris, January 2018.
- Maculopathie diabétique : facteurs thérapeutiques systémiques, anti VEGF, cortisone et laser, Jeudi de Jules Gonin, Lausanne, 29th January 2018.
- Polypoidal Cnv In Caucasian Population, Isopt Clinical, Tel Aviv, 1-3 March 2018.
- Age-related macular degeneration, Clinique de Montchoisi, Lausanne, May the 31st 2018.
- OCT angiography in AMD, Geneva, Imaging Symposium, Clinique de la colline, June 21th 2018, Biomarqueurs d'activité en OCTA de la DMLA néovasculaire
- When should I refer my patient with AMD ? Fall seminar, Coppet, Switzerland, 4th of October 2018.
- AOP International, Paris, Palais Brongniart, 14-15 December 2018.
- Influence of structural SD-OCT characteristics in the detection of choroidal neovascularization due to AMD using OCT angiography, OCT 6th Congress, Roma, December 2018.
- OCT-A : Quand est-elle vraiment utile ? Retina Update, Clinique la colline Genève, 31 janvier 2019.
- Biomarqueurs OCT et pathologies maculaires : sine qua non? Retina Update, Clinique la colline Genève, 31 janvier 2019.
- Accord entre l'angiographie avec produit de contraste et l'OCT angiographie dans la DMLA néovasculaire, SFR Paris, 19 janvier 2019.
- Sensitivity of OCT angiography in the detection of choroidal neovascularization in wet AMD in relation to anatomical features on SDOCT, Macula Society, Bonita Springs, 14 février 2019.
- Diagnostic and treatment of inflammatory neo vessels. SAO Luzern, 6d March 2019.
- Pachychoroid: A New Classification and Clinical Applications of Relevant Results of Recent Studies SSO, Lausanne 27, August 2020.
- Prise en charge de la maculopathie diabétique : laser micropulsé, anti VEGF ou corticoïdes ? Formation continue en Ophtalmologie, Clinique de la Coline, Genève, Octobre 2020.
- Traitements de la DMLA humide en Suisse : Place du Brolucizumab, de l'Aflibercept, du Ranibizumab et du Bevacizumab. Formation continue en Ophtalmologie, Clinique de la Coline, Genève, Octobre 2020.
- Premières expériences avec le Brolucizumab en Suisse. Formation continue en Ophtalmologie, Clinique de la Coline, Geneve Octobre 2020.
- Ophthalmology and Covid-19: what we have learnt? Forum pour la formation médicale - WebUp Experten-Forum «Update Ophtalmologie». Zoom event. October 21st 2021.
- Have we arrived at the end of the road for advancements in nAMD treatment?, Bayer-sponsored symposium at the Virtual COPHY Global Congress, June 2022.
- Perfusion choroïdienne et activité sportive, Swiss Visio Symposium "Les beaux yeux du sport", Lausanne, 22 septembre 2022.



- Comparison perfusion time in fluoresceine angiography/digital values in OCT-Angiography / Comparaison temps de perfusion en angiographie avec produit de contraste et valeurs métriques de l'OCT angiographie. Ophthalmic Imaging Congress, Paris, September 23rd 2022.
- Y-a-t-il une place pour l'utilisation des corticostéroïdes en intravitréen dans la DMLA exsudative? Colloque sur les nouveaux traitements en rétine médicale et chirurgicale, Centre Ophtalmologique La Colline, Genève, 1er décembre 2022.
- Cas de DMLA avec mauvaise réponse à l'induction: Que faire ? Journée nationale de la Société Française de Rétine, Paris, 21 Janvier 2023.
- Influence of Retinal and Choroidal Perfusion Times Measured Using Dye Angiography on Quantitative Analysis of OCT-Angiography, 46th Macula Society Annual Meeting, Miami, 17th February 2023.
- Vabysmo First Line - The Early Results: Own OCT examples of treatment-naïve patients, 7th Congress of the Swiss Academy of Ophthalmology, Lucern, 2 March 2023.
- Recommendations for intravitreal injection, 7th Congress of the Swiss Academy of Ophthalmology, Lucern, 3 March 2023.
- Traitement de l'atrophie géographique: Le Pegcetacoplan bientôt enregistré en Suisse? Résultats des études pivotales Oaks and Derby, Centre Ophtalmologique La Colline, Genève, 30 mars 2023.
- Improved retina fluid control with faricimab in phase 3 trials in wet AMD and DME, SwissVisio Montchoisi Symposium d'ophtalmologie, Crissier, 30 March 2023.
- DMLA : "La cécité est-elle encore une fatalité ?", Clinique de Montchoisi, Lausanne, 27 avril 2023.
- Dégénérescence maculaire liée à l'âge: nouvelles options thérapeutiques, Retina Suisse 44th annual meeting, Bern, 29 April 2023.
- Pigment epithelium detachment in age-related macular degeneration, Oftacafé – Retina Symposium, Lugano, 18 May 2023.
- Virtual Workshop on Evaluating Vascular Stabilization with Faricimab: Current Status and Future Directions, the Angiogenesis Foundation, July 12th and 13th 2023.
- Pick up the OCT angiography findings requiring dye angiography, SOG/SSO Swiss Society of Ophthalmology, Lausanne, 1st September 2023.
- Illustrative cases presentation: the answer was in the angiography...spot it! A. Giocatni-Aurégan, M. Munk, A. Ambresin, SOG/SSO Swiss Society of Ophthalmology, Lausanne, 1st September 2023.
- Chaudhary V, Ambresin A, Kotecha A, Willis JR, Souverain A, Shildkrot YE, Swaminathan B, Margaron P. Personalised faricimab dosing increased the proportion of patients with nAMD achieving Q16W dosing in year 2 of TENAYA/LUCERNE, while maintaining functional and anatomical outcomes [Conference presentation]. Retina Society 56th Annual Scientific Meeting; 2023 Oct 13; Lisbon, Portugal.
- Ambresin A, Owyla N. Photobiomodulation bei trockener AMD [Conference presentation]; 2023 Nov 30; SVRG Swiss Retina Update 2023, Zurich, Switzerland.

### Free papers congresses as speaker

- Idiopathic epiretinal membrane (ERM) en-face visualisation: comparison of Heidelberg multicolour imaging technique with Optovue en-face OCT. JA Pournaras, M.Zola, I. Pappasavvas, L. Marchionno, A. Ambresin, Euretina 2018, Vienna.
- Influence of structural SD-OCT characteristics in the detection of choroidal neovascularization due to AMD using OCT angiography. Pappasavvas I, Dirani A, Zola M, Pournaras JA, Ambresin A. Euretina 2018, Vienna.
- Influence of structural SD-OCT characteristics in the detection of choroidal neovascularization due to AMD using OCT angiography. Ambresin A. February 2019, Bonita Springs, Florida, USA.
- SD-OCT et angio-OCT d'une maculopathie moyenne paracentrale aiguë (PAMM) chez un patient drépanocytaire, à propos d'un cas. SFO 2019, Paris France. S Roemer, A Ambresin
- Reliability of OCTA in the diagnosis of fovea plana. SFO 2019. Paris, France, 13 mai 2019. Ambresin A
- SD-OCT et angio-OCT d'une maculopathie moyenne paracentrale aiguë (PAMM) chez un patient drépanocytaire, à propos d'un cas. SFO, Paris, mai 2019. S Roemer, A Ambresin.
- Aneurysmal type 1 neovascularisation. A. Ambresin. Euretina, Septembre Paris 2019.
- Pathogenesis of retinal vascular diseases. A. Ambresin. Euretina, Septembre, Paris 2019.
- OCTs in age related macular degeneration. Euretina, Septembre Paris 2019.
- October 4th 2019, Paris Congrès 2020 - Imagerie en Ophtalmologie : de la théorie à la pratique, New Cap Event Center .
- OCT and OCT angiography based management of AMD, Present indications for the use of fluorescein angiography. A.Ambresin, EVER, Nice, 18 octobre 2019.
- The spectrum of disorders related to pachychoroid: an EDI-OCT evaluation. Ambresin EVER, Nice, 18 octobre 2019.
- The importance of monitoring wet Age-related Macular Degeneration patients during Coronavirus disease 2019 pandemic: A retrospective study of assessment of functional and structural outcomes. G.N. Tsiropoulos, R. Vallée, D. Gallo Castro, A. Ambresin. Euretina, virtual meeting, 09-12 September 2021.
- Patients' opinion on the monitoring of their wet age-related macular degeneration during Coronavirus disease 2019 pandemic and on the importance of telemedicine. G.N. Tsiropoulos, R. Vallée, C. Calci, D. Gallo Castro, A. Ambresin. Euretina, virtual meetinf, 09-12 September 2021.
- Influence of retinal and choroidal perfusion times measured using dye angiography on quantitative analysis of OCT-angiography. A. Ambresin, D. Körpe, R. Vallée, D. Gallo Castro, G.N. Tsiropoulos. Euretina, virtual meeting, 09-12 September 2021.
- Influence of retinal and choroidal perfusion times measured using dye angiography on quantitative analysis of OCT-angiography. A. Ambresin, G.N. Tsiropoulos, R. Vallée., D. Gallo Castro, Dilsah Körpe. IOCS, Kyoto, 24-26 September 2021.
- Short-term outcomes of switching to intravitreal faricimab in patients with treatment-resistant neovascular age-related macular degeneration, M. Barbosa, N. Owlya, A. Nascimbeni, Y. Pannatier-Schuetz,

D. Gallo Castro, A. Ambresin, SOG/SSO Swiss Society of Ophthalmology, Lausanne, 1 September 2023.

- Short-term outcomes of switching to intravitreal faricimab in patients with treatment-resistant neovascular age-related macular degeneration, M. Barbosa, N. Owlya, A. Nascimbeni, Y. Pannatier-Schuetz, D. Gallo Castro, A. Ambresin, 23rd Euretina Congress, Amsterdam, October 2023.
- Personalised faricimab dosing increased the proportion of patients with nAMD achieving Q16W dosing in year 2 of TENAYA/LUCERNE, while maintaining functional and anatomical outcomes, V. Chaudhary, A. Ambresin, A. Kotecha, J. R. Willis, A. Souverain, Y.E. Shildkrot, B. Swaminathan, P. Margaron, 127th annual meeting of the American Academy of Ophthalmology, San Francisco, November 2023.

### Poster presentations

- OCT-Angiography as a help in the diagnosis of a laser pointer retinal injury .M Sherif, J Berthoud, A Ambresin; SOG/SSO Swiss Society of Ophthalmology, Fribourg 2018.
- Natural History of PAMM: Zola M, Ambresin A, Borruat FX, Mantel I, SOG/SSO Swiss Society of Ophthalmology, Fribourg 2018.
- Vasculitis and subfoveal choroidal neovessels in a case of Multifocal Pattern Dystrophy. Roquelaure D, Rossi D, Ambresin A, Guex Crosier Y. SOG/SSO Swiss Society of Ophthalmology, Fribourg 2018.
- Comparison of SD OCT and OCTA biomarkers of activity in wet AMD. Ambresin A, Bergin C, Naso S, SOG, Fribourg 2018.
- Regression of optic disc neovascularization in a patient with Behçet's disease treated with oral corticosteroids and adalimumab. Pappasavvas I, Ambresin A, Pournaras J-A, Henchoz L, Vaudaux J. SOG/SSO Swiss Society of Ophthalmology, Fribourg 2018.
- Atypical retro internal limiting membrane hemorrhage in homozygous sickle-cell disease: a case report, Voide N, Mantel I, Ambresin A, EPOS 2018, Oslo, Norway.
- OCT-Angiography as a help in the diagnosis of a laser pointer retinal injury. M Sherif, J Berthoud, A Ambresin; OCTA congress; Rome, December 2018.
- Bilateral vascular anomalies in Coats disease suggest concurrent retinal vascular disease. Zola M, A. Ambresin, F Munier, ARVO, Vancouver, 2019.
- Atypical retro internal limiting membrane hemorrhage in homozygous sickle cell disease. SOG/SSO Swiss Society of Ophthalmology, Interlaken, 30 aout 2019, Voide N, Ambresin A
- Optical coherence tomography analysis of cystoid macular edema in retinal dystrophy treated with oral acetazolamide: 2 cases. V Chatzistergiou, A.Ambresin. SOG/SSO Swiss Society of Ophthalmology, Interlaken, 30th Aout 2019.
- Bilateral ocular melanocytosis-like fundus presentation in patients with sectorial relative pachychoroid: case reports of six patients, I Pappasavvas, A Ambresin, SOG/SSO Swiss Society of Ophthalmology, Interlaken, 30 August 2019.
- Efficacy of Tocilizumab in Stabilizing Post-Surgical Inflammatory Refractory Macular Edema: a report of two cases. E. Meduri, G.N. Tsiropoulos, C. Ribbi, Aude Ambresin, SOG/SSO Swiss Society of Ophthalmology, Saint Gall, 26-27 August 2021.

- Monitoring wet Age-related Macular Degeneration patients during Coronavirus disease 2019 pandemic: A retrospective study of assessment of functional and structural outcomes. G.N. Tsiropoulos, R. Vallée, D. Gallo Castro, A. Ambresin, SOG/SSO Swiss Society of Ophthalmology, Saint Gall, 26-27 August 2021.
- Patient opinion on the monitoring of their wet age related macular degeneration during coronavirus disease 2019 pandemic and on the importance of telemedicine. Georgios N. Tsiropoulos, Rodolphe Vallée, Coraline Calci, Daniela Gallo Castro, Aude Ambresin. EVER, Nice, 30 September – 2 October 2021.
- Monitoring wet Age related Macular Degeneration patients during Coronavirus disease 2019 pandemic: A retrospective study of assessment of functional and structural outcomes. Georgios N. Tsiropoulos, Rodolphe Vallée, Daniela Gallo Castro, Aude Ambresin. EVER, Nice, 30 September – 2 October 2021.
- Rapidly progressive visual field deterioration in a glaucomatous patient treated with several anti-VEGF injections for neovascular AMD: a Case report. Coraline Calci, Daniela Gallo Castro, André Mermoud, Aude Ambresin, 128e congrès international de la Société Française d’Ophtalmologie (SFO), Paris, 7-9 May 2022.
- Rapidly progressive visual field deterioration in a glaucomatous patient treated with several anti-VEGF injections for neovascular AMD: a Case report. Coraline Calci, Daniela Gallo Castro, André Mermoud, Aude Ambresin. SOG/SSO Swiss Society of Ophthalmology, Basel, 24-26 August 2022.
- Retreatment of recurrent wet AMD with an alternative intravitreal anti-VEGF drug after ocular inflammation following intravitreal brolocizumab injection : about two cases. El Karmy Badiâa, Daniela Gallo Castro, Aude Ambresin. SOG/SSO Swiss Society of Ophthalmology, Basel, 24-26 August 2022.
- Cardiovascular risk prediction by artificial neural networks using dye-based angiography and OCT angiography data. Rodolphe Vallée, Aude Ambresin. SOG/SSO Swiss Society of Ophthalmology, Basel, 24-26 August 2022.
- Torpedo maculopathy: cases series presentation of an underdiagnosed rare condition using multi-modal imaging, N. Owlya, A. Nascimbeni, Y. Pannatier-Schuetz, D. Gallo Castro, A. Ambresin, 129e Congrès international de la Société Française d’Ophtalmologie (SFO), Paris, 6-8 May 2023.
- Increased relevance of clinical and SD-OCT cardinal signs recognition in patients with the underdiagnosed macular telangiectasia type 2 (MACTEL) disease, A. Bechara Ghobril, J.-A. Pournaras, A. Ambresin, 129e Congrès international de la Société Française d’Ophtalmologie (SFO), Paris, 6-8 May 2023.
- Ocular manifestations in a context of primary hyperparathyroidism: a report of two cases, M. Barbosa, Y. Pannatier-Schuetz, D. Gallo Castro, A. Nascimbeni, A. Ambresin, 129e Congrès international de la Société Française d’Ophtalmologie (SFO), Paris, 6-8 May 2023.
- Analyse qualitative en SD-OCT de la réponse thérapeutique immédiate après un switch par faricimab hors indication chez des patients souffrant de néovaisseaux choroïdiens récidivants sous maculaires secondaires à une chorioretinopathie séreuse centrale, A. Hebben A. Ambresin, 129e Congrès international de la Société Française d’Ophtalmologie (SFO), Paris, 6-8 May 2023.
- Two-year results from the Swiss cohort of a non-interventional study investigating real-world proactive dosing regimens with intravitreal aflibercept in patients with nAMD: XTEND study, K. Hatz, A. Ambresin, M. Schmid, C. Prünste, D. Barthelmes, T. Machewitz, H. Allmeier, G. Márk Somfai, SOG/SSO Swiss Society of Ophthalmology, Lausanne, 30 August 2023 -1 September 2023.

- Functional and anatomical outcomes of patients treated with intravitreal aflibercept for refractory diabetic macular edema switched to faricimab: an interim analysis, N. Owlya, A. Hebben, M. Barbosa, D. Gallo Castro, AC Nascimbeni, Y. Pannatier-Schuetz, A. Ambresin, SOG/SSO Swiss Society of Ophthalmology, Lausanne, 30 August 2023 -1 September 2023.
- Torpedo maculopathy: cases series presentation of an underdiagnosed rare condition using multi-modal imaging, N. Owlya, A.C. Nascimbeni, Y. Pannatier-Schuetz, D. Gallo Castro, A. Ambresin, SOG/SSO Swiss Society of Ophthalmology, Lausanne, 30 August 2023 -1 September 2023.
- Ocular manifestations in a context of primary hyperparathyroidism: a report of two cases M. Barbosa, Y. Pannatier-Schuetz, D. Gallo Castro, AC Nascimbeni, A. Ambresin SOG/SSO Swiss Society of Ophthalmology, Lausanne, 30 August 2023 -1 September 2023.
- Acute intraocular pressure elevations following intravitreal anti-VEGF injections in patients with wet AMD: a preliminary report, M. Barbosa, C. Calci, N. Owlya, Y. Pannatier-Schuetz, D. Gallo Castro, A. C. Nascimbeni, A. Ambresin, 23rd Euretina Congress, Amsterdam, October 2023.
- Functional and anatomical outcomes of patients treated with intravitreal aflibercept for refractory diabetic macular edema switched to faricimab: an interim analysis, N. Owlya, Y. Pannatier-Schuetz, D. Gallo Castro, A. C. Nascimbeni, A. Ambresin, 23rd Euretina Congress, Amsterdam, October 2023.
- Increased relevance of clinical and SD-OCT cardinal signs recognition in patients with the underdiagnosed macular telangiectasia type 2 (MACTEL) disease, A. Bechara Ghobril, J.-A. Pournaras, A. Ambresin, 23rd Euretina Congress, Amsterdam, October 2023.

## **HONORS**

- Chitoroaga N, Ambresin A, Petrovic A. Challenges in managing post-Lyell ocular complications: addressing severe ocular surface disease during intravitreal injections. Théa Trophy Contest [Candidat]; 2023.